Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Panel Gives Thumbs-Up for Entyvio, Official Nod Expected This Month
June 11, 2018
- Further Price Cuts for Off-Patent Drugs Erased from Draft Honebuto Paper
June 11, 2018
- Panel Members Positive about Going Digital on Package Inserts: HSC
June 11, 2018
- Govt Should Screen Drug Promotion Material, Scope of Information Provided: HSC Member
June 8, 2018
- Experts Support Plan to Seize Improperly Earned Revenue as in Diovan Case: HSC
June 8, 2018
- AMED Discloses Individual R&D Project Funding; 31 Receive Funding of Over 1 Billion Yen
June 7, 2018
- Deregulation Panel Pushes PMDA to Digitalize Process
June 6, 2018
- Reward Innovation to Solve Social Challenges: LDP Study Group
June 6, 2018
- Japan Eyes Economic Assessments for New Drug Listing: Draft Honebuto Paper
June 6, 2018
- Large Vessel Vasculitis to Be Added to Significant Adverse Reactions for G-CSF Preparations: MHLW
June 6, 2018
- Invoice Price Rates Decline Only for Long-listed Drugs at 3 Companies: MHLW Survey
June 4, 2018
- “Preclinical Registry” Will Accelerate Drug Discovery in Field of Dementia: AMED President
June 4, 2018
- AMED to Increase Transparency in Funding by Opening Up Research Database to Public
June 1, 2018
- Ex-Minister Shiozaki Holds Talks with PhRMA, EFPIA
June 1, 2018
- MHLW to End Manufacturing Record Inspection for Kaketsuken’s Plasma Fraction Products
June 1, 2018
- MHLW Positive on Enshrining Conditional Approval, Sakigake Schemes into Law: Official
May 31, 2018
- Japan’s First Biosimilars for Enbrel, Herceptin Added to NHI Price List
May 30, 2018
- Honebuto Policy Won’t Include Numerical Target for Social Security Costs
May 29, 2018
- Takeda’s Entyvio Up for MHLW Panel Review on June 8
May 28, 2018
- MHLW Grants Orphan Status to Vyndaqel, Burosumab
May 28, 2018
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…